Form 4: CRISPR Therapeutics COO Julianne Bruno Reports Stock Transactions
SEC Form 4
Julianne Bruno, COO of CRISPR Therapeutics, reports the acquisition and disposal of common shares and restricted stock units related to vesting and tax obligations.
Summary
- Julianne Bruno, the Chief Operating Officer of CRISPR Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
- On March 10, 2025, 2,399 restricted stock units vested and were converted to common shares, while 2,399 shares were disposed of.
- On March 11, 2025, 1,198 common shares were sold at $42.42 to cover tax obligations related to vesting restricted stock units.
- Also on March 11, 2025, 435 restricted stock units vested and were converted to common shares.
- On March 12, 2025, 190 common shares were sold at $43.32 to cover tax obligations.
- Following these transactions, Bruno directly owns 8,508 common shares and indirectly owns 7,088 shares through The Julianne Bruno 2022 GRAT.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions, indicating a neutral sentiment.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency regarding the transactions of company insiders.
Comparison to Industry Standards
- Executive compensation packages often include restricted stock units that vest over time.
- The sale of shares to cover tax obligations upon vesting is a standard practice.
- Similar filings are made by executives at comparable companies like Editas Medicine and Intellia Therapeutics.
Stakeholder Impact
- The transactions have a minor impact on shareholders as they reflect routine executive compensation and tax-related sales.
Key Dates
| Date | Description |
|---|---|
| March 10, 2023 | Date of grant for 9,593 Common Shares RSU award, vesting quarterly from March 10, 2024. |
| March 11, 2021 | Date of grant for 1,740 Common Shares RSU award, vesting quarterly from March 11, 2022. |
| March 10, 2024 | First vesting date for one quarter of the 9,593 Common Shares RSU award granted on March 10, 2023. |
| March 11, 2022 | First vesting date for one quarter of the 1,740 Common Shares RSU award granted on March 11, 2021. |
| March 10, 2025 | RSU vesting and conversion to common shares; disposal of shares. |
| March 11, 2025 | Sale of common shares to cover tax obligations; RSU vesting and conversion to common shares. |
| March 12, 2025 | Sale of common shares to cover tax obligations; filing date of Form 4. |
| March 10, 2026 | Third vesting date for one quarter of the 9,593 Common Shares RSU award granted on March 10, 2023. |
| March 10, 2027 | Final vesting date for one quarter of the 9,593 Common Shares RSU award granted on March 10, 2023. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.